{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:47:53Z","timestamp":1776872873425,"version":"3.51.2"},"reference-count":91,"publisher":"JLE","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.nephro.2021.03.001","type":"journal-article","created":{"date-parts":[[2021,4,25]],"date-time":"2021-04-25T11:19:16Z","timestamp":1619349556000},"page":"S1-S10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"S","title":["Pathophysiology, diagnosis, and treatment of membranous nephropathy"],"prefix":"10.1684","volume":"17","author":[{"given":"Jens","family":"Lutz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","reference":[{"issue":"4","key":"10.1016\/j.nephro.2021.03.001_bib0460","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3390\/biomedicines7040086","article-title":"Primary membranous glomerulonephritis: the role of serum and urine biomarkers in patient management","volume":"7","author":"Maifata","year":"2019","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.nephro.2021.03.001_bib0465","article-title":"Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy","volume":"38","author":"Seitz-Polski","year":"2018","journal-title":"Biosci Rep"},{"issue":"4","key":"10.1016\/j.nephro.2021.03.001_bib0470","first-page":"599","article-title":"A follow-up analysis of positron emission tomography\/computed tomography in detecting hidden malignancies at the time of diagnosis of membranous nephropathy","volume":"35","author":"Feng","year":"2020","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"10.1016\/j.nephro.2021.03.001_bib0475","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1038\/sj.ki.5001790","article-title":"Membranous nephropathy and cancer: epidemiologic evidence and determinants of high-risk cancer association","volume":"70","author":"Lefaucheur","year":"2006","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.nephro.2021.03.001_bib0480","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000487136","article-title":"The genetic and environmental factors of primary membranous nephropathy: an overview from China","volume":"4","author":"Zhang","year":"2018","journal-title":"Kidney Dis (Basel)"},{"issue":"26","key":"10.1016\/j.nephro.2021.03.001_bib0485","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMoa012895","article-title":"Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies","volume":"346","author":"Debiec","year":"2002","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.nephro.2021.03.001_bib0490","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1681\/ASN.2017020178","article-title":"PLA2R and THSD7A: disparate paths to the same disease?","volume":"28","author":"Beck","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.nephro.2021.03.001_bib0495","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1172\/JCI85265","article-title":"Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy","volume":"126","author":"Tomas","year":"2016","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.nephro.2021.03.001_bib0500","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.kint.2019.09.014","article-title":"Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy","volume":"97","author":"Sethi","year":"2020","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.nephro.2021.03.001_bib0505","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1681\/ASN.2018080852","article-title":"Exostosin 1\/exostosin 2-associated membranous nephropathy","volume":"30","author":"Sethi","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.nephro.2021.03.001_bib0510","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/eci.12292","article-title":"Serum with phospholipase A2 receptor autoantibodies interferes with podocyte adhesion to collagen","volume":"44","author":"Skoberne","year":"2014","journal-title":"Eur J Clin Invest"},{"issue":"11","key":"10.1016\/j.nephro.2021.03.001_bib0515","doi-asserted-by":"crossref","first-page":"7935","DOI":"10.1074\/jbc.M113.512780","article-title":"Complex determinants in specific members of the mannose receptor family govern collagen endocytosis","volume":"289","author":"Jurgensen","year":"2014","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.nephro.2021.03.001_bib0520","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/MNH.0000000000000459","article-title":"Unmet challenges in membranous nephropathy","volume":"28","author":"Salant","year":"2019","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"1","key":"10.1016\/j.nephro.2021.03.001_bib0525","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.nephro.2021.03.001_bib0530","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.ajkd.2016.01.030","article-title":"Membranous nephropathy: a journey from bench to bedside","volume":"68","author":"Francis","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"2\u20133","key":"10.1016\/j.nephro.2021.03.001_bib0535","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0304-4165(02)00319-7","article-title":"The mannose receptor family","volume":"1572","author":"East","year":"2002","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"10.1016\/j.nephro.2021.03.001_bib0540","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0165-6147(99)01300-0","article-title":"Receptors for a growing family of secreted phospholipases A2","volume":"20","author":"Lambeau","year":"1999","journal-title":"Trends Pharmacol Sci"},{"issue":"15","key":"10.1016\/j.nephro.2021.03.001_bib0545","doi-asserted-by":"crossref","first-page":"8963","DOI":"10.1074\/jbc.270.15.8963","article-title":"The human 180-kDa receptor for secretory phospholipases A2. Molecular cloning, identification of a secreted soluble form, expression, and chromosomal localisation","volume":"270","author":"Ancian","year":"1995","journal-title":"J Biol Chem"},{"issue":"9","key":"10.1016\/j.nephro.2021.03.001_bib0550","doi-asserted-by":"crossref","first-page":"6414","DOI":"10.1016\/S0021-9258(18)42711-1","article-title":"Characterisation of a high affinity binding site for pancreatic-type phospholipase A2 in the rat. Its cellular and tissue distribution","volume":"267","author":"Hanasaki","year":"1992","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.nephro.2021.03.001_bib0555","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1074\/jbc.271.1.250","article-title":"Endocytic properties of the M-type 180-kDa receptor for secretory phospholipases A2","volume":"271","author":"Zvaritch","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nephro.2021.03.001_bib0560","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.3389\/fimmu.2019.01809","article-title":"Immunological pathogenesis of membranous nephropathy: focus on PLA2R1 and its role","volume":"10","author":"Liu","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.nephro.2021.03.001_bib0565","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/ni.2184","article-title":"A new synthesis for antibody-mediated immunity","volume":"13","author":"Casadevall","year":"2011","journal-title":"Nat Immunol"},{"issue":"24","key":"10.1016\/j.nephro.2021.03.001_bib0570","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1016\/j.jmb.2017.10.019","article-title":"Structure of human M-type phospholipase A2 receptor revealed by cryo-electron microscopy","volume":"429","author":"Dong","year":"2017","journal-title":"J Mol Biol"},{"key":"10.1016\/j.nephro.2021.03.001_bib0575","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1146\/annurev.cellbio.12.1.575","article-title":"Endocytosis and molecular sorting","volume":"12","author":"Mellman","year":"1996","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"2","key":"10.1016\/j.nephro.2021.03.001_bib0580","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2014050502","article-title":"Identification of a major epitope recognised by PLA2R autoantibodies in primary membranous nephropathy","volume":"26","author":"Fresquet","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.nephro.2021.03.001_bib0585","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1681\/ASN.2013121315","article-title":"Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy","volume":"26","author":"Kao","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.nephro.2021.03.001_bib0590","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1681\/ASN.2013040430","article-title":"Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy","volume":"25","author":"Hoxha","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.nephro.2021.03.001_bib0595","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1681\/ASN.2013020185","article-title":"Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy","volume":"25","author":"van den Brand","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2021.03.001_bib0600","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3389\/fmed.2019.00241","article-title":"Immune-monitoring disease activity in primary membranous nephropathy","volume":"6","author":"Cravedi","year":"2019","journal-title":"Front Med (Lausanne)"},{"issue":"30","key":"10.1016\/j.nephro.2021.03.001_bib0605","doi-asserted-by":"crossref","first-page":"e1243","DOI":"10.1097\/MD.0000000000001243","article-title":"Membranous nephropathy associated with immunological disorder-related liver disease: a retrospective study of 10 cases","volume":"94","author":"Dauvergne","year":"2015","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.nephro.2021.03.001_bib0610","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/MAJ.0b013e318267b5cd","article-title":"Detection of anti-PLA2R autoantibodies and IgG subclasses in post-allogeneic hematopoietic stem cell transplantation membranous nephropathy","volume":"346","author":"Huang","year":"2013","journal-title":"Am J Med Sci"},{"issue":"6","key":"10.1016\/j.nephro.2021.03.001_bib0615","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1681\/ASN.2010090967","article-title":"Anti-phospholipase A2 receptor antibody in membranous nephropathy","volume":"22","author":"Qin","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"24","key":"10.1016\/j.nephro.2021.03.001_bib0620","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.nephro.2021.03.001_bib0625","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/jcp.21990","article-title":"Thrombospondin type I domain containing 7A (THSD7A) mediates endothelial cell migration and tube formation","volume":"222","author":"Wang","year":"2010","journal-title":"J Cell Physiol"},{"issue":"5","key":"10.1016\/j.nephro.2021.03.001_bib0630","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1681\/ASN.2018090941","article-title":"Thrombospondin type 1 domain-containing 7A localises to the slit diaphragm and stabilises membrane dynamics of fully differentiated podocytes","volume":"30","author":"Herwig","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.nephro.2021.03.001_bib0635","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/modpathol.2017.163","article-title":"Tissue staining for THSD7A in glomeruli correlates with serum antibodies in primary membranous nephropathy: a clinicopathological study","volume":"31","author":"Sharma","year":"2018","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.nephro.2021.03.001_bib0640","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1080\/0886022X.2018.1456457","article-title":"An update on clinical significance of use of THSD7A in diagnosing idiopathic membranous nephropathy: a systematic review and meta-analysis of THSD7A in IMN","volume":"40","author":"Ren","year":"2018","journal-title":"Ren Fail"},{"issue":"1","key":"10.1016\/j.nephro.2021.03.001_bib0645","doi-asserted-by":"crossref","first-page":"67","DOI":"10.18632\/oncotarget.19859","article-title":"Urine anti-PLA2R antibody is a novel biomarker of idiopathic membranous nephropathy","volume":"9","author":"Wang","year":"2018","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.nephro.2021.03.001_bib0650","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1053\/j.ajkd.2019.05.021","article-title":"Treatment of membranous nephropathy in patients with THSD7A antibodies using immunoadsorption","volume":"74","author":"Weinmann-Menke","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"10.1016\/j.nephro.2021.03.001_bib0655","doi-asserted-by":"crossref","first-page":"e0138841","DOI":"10.1371\/journal.pone.0138841","article-title":"Prevalence of enhanced granular expression of thrombospondin type-1 domain-containing 7A in the glomeruli of Japanese patients with idiopathic membranous nephropathy","volume":"10","author":"Iwakura","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.nephro.2021.03.001_bib0660","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1681\/ASN.2016010050","article-title":"An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy","volume":"28","author":"Hoxha","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.nephro.2021.03.001_bib0665","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s12882-019-1489-5","article-title":"Expression of THSD7A in neoplasm tissues and its relationship with proteinuria","volume":"20","author":"Xian","year":"2019","journal-title":"BMC Nephrol"},{"issue":"6","key":"10.1016\/j.nephro.2021.03.001_bib0670","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1053\/j.ajkd.2018.10.009","article-title":"VEGF-A links angiolymphoid hyperplasia with eosinophilia (ALHE) to THSD7A membranous nephropathy: a report of 2 cases","volume":"73","author":"Matsumoto","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.nephro.2021.03.001_bib0675","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00428-019-02558-0","article-title":"Clinicopathological characteristics of thrombospondin type 1 domain-containing 7A-associated membranous nephropathy","volume":"474","author":"Hara","year":"2019","journal-title":"Virchows Arch"},{"key":"10.1016\/j.nephro.2021.03.001_bib0680","doi-asserted-by":"crossref","first-page":"102308","DOI":"10.1016\/j.jaut.2019.102308","article-title":"Autoantigens PLA2R and THSD7A in membranous nephropathy share a common epitope motif in the N-terminal domain","volume":"106","author":"Fresquet","year":"2020","journal-title":"J Autoimmun"},{"issue":"7","key":"10.1016\/j.nephro.2021.03.001_bib0685","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1009742","article-title":"Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy","volume":"364","author":"Stanescu","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2021.03.001_bib0690","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.3389\/fimmu.2018.03035","article-title":"Antigen-specific IgG subclasses in primary and malignancy-associated membranous nephropathy","volume":"9","author":"von Haxthausen","year":"2018","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.nephro.2021.03.001_bib0695","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1681\/ASN.2017070805","article-title":"The most N-terminal region of THSD7A is the predominant target for autoimmunity in THSD7A-associated membranous nephropathy","volume":"29","author":"Seifert","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.nephro.2021.03.001_bib0700","first-page":"328","article-title":"CD20-positive infiltrates in human membranous glomerulonephritis","volume":"18","author":"Cohen","year":"2005","journal-title":"J Nephrol"},{"issue":"9981","key":"10.1016\/j.nephro.2021.03.001_bib0705","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/S0140-6736(15)60731-0","article-title":"Pathophysiological advances in membranous nephropathy: time for a shift in patient's care","volume":"385","author":"Ronco","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.nephro.2021.03.001_bib0710","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.nephro.2021.03.001_bib0715","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1681\/ASN.2017070734","article-title":"Phospholipase A2 receptor 1 epitope spreading at baseline predicts reduced likelihood of remission of membranous nephropathy","volume":"29","author":"Seitz-Polski","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2021.03.001_bib0720","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3389\/fneur.2018.00997","article-title":"Chronic inflammatory demyelinating polyneuropathy with concurrent membranous nephropathy: an anti-paranode and podocyte protein antibody study and literature survey","volume":"9","author":"Hashimoto","year":"2018","journal-title":"Front Neurol"},{"issue":"4","key":"10.1016\/j.nephro.2021.03.001_bib0725","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1161\/ATVBAHA.117.310594","article-title":"Genome-wide association and functional studies identify SCML4 and THSD7A as novel susceptibility genes for coronary artery disease","volume":"38","author":"Li","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/j.nephro.2021.03.001_bib0730","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/ndt\/gfx235","article-title":"Glomerular mannose-binding lectin deposition in intrinsic antigen-related membranous nephropathy","volume":"33","author":"Hayashi","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.nephro.2021.03.001_bib0735","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20180131","article-title":"Human anti-thrombospondin type 1 domain-containing 7A antibodies induce membranous nephropathy through activation of lectin complement pathway","volume":"38","author":"Wang","year":"2018","journal-title":"Biosci Rep"},{"issue":"2","key":"10.1016\/j.nephro.2021.03.001_bib0740","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.kint.2018.10.018","article-title":"Management and treatment of glomerular diseases (part 1): conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference","volume":"95","author":"Floege","year":"2019","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.nephro.2021.03.001_bib0745","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.2215\/CJN.07210810","article-title":"Anti-phospholipase A(2) receptor antibodies correlate with clinical status in idiopathic membranous nephropathy","volume":"6","author":"Hofstra","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.nephro.2021.03.001_bib0750","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1681\/ASN.2009080861","article-title":"Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy","volume":"21","author":"Polanco","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.nephro.2021.03.001_bib0755","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1681\/ASN.2015111262","article-title":"Membranous nephropathy: quantifying remission duration on outcome","volume":"28","author":"Cattran","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.nephro.2021.03.001_bib0760","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000045998","article-title":"Remission achieved in chronic nephropathy by a multidrug approach targeted at urinary protein excretion","volume":"88","author":"Ruggenenti","year":"2001","journal-title":"Nephron"},{"issue":"9","key":"10.1016\/j.nephro.2021.03.001_bib0765","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrneph.2017.92","article-title":"Treatment of membranous nephropathy: time for a paradigm shift","volume":"13","author":"Ruggenenti","year":"2017","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"10.1016\/j.nephro.2021.03.001_bib0770","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1681\/ASN.2007090970","article-title":"Role of remission clinics in the longitudinal treatment of CKD","volume":"19","author":"Ruggenenti","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"9268","key":"10.1016\/j.nephro.2021.03.001_bib0775","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/S0140-6736(00)04728-0","article-title":"Progression, remission, regression of chronic renal diseases","volume":"357","author":"Ruggenenti","year":"2001","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.nephro.2021.03.001_bib0780","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1046\/j.1523-1755.2003.00832.x","article-title":"Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies","volume":"63","author":"Campbell","year":"2003","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.nephro.2021.03.001_bib0785","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0272-6386(04)00809-1","article-title":"Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review","volume":"44","author":"Perna","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.nephro.2021.03.001_bib0790","first-page":"61","article-title":"The natural history of renal function in untreated idiopathic membranous glomerulonephritis in adults","volume":"22","author":"Davison","year":"1984","journal-title":"Clin Nephrol"},{"issue":"11","key":"10.1016\/j.nephro.2021.03.001_bib0795","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1080\/17512433.2016.1225497","article-title":"Pharmacological treatment of primary membranous nephropathy in 2016","volume":"9","author":"van de Logt","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"15","key":"10.1016\/j.nephro.2021.03.001_bib0800","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1056\/NEJM198404123101503","article-title":"Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy","volume":"310","author":"Ponticelli","year":"1984","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.nephro.2021.03.001_bib0805","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1056\/NEJM198901053200102","article-title":"A randomised trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy","volume":"320","author":"Ponticelli","year":"1989","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.nephro.2021.03.001_bib0810","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/ki.1995.453","article-title":"A 10-year follow-up of a randomised study with methylprednisolone and chlorambucil in membranous nephropathy","volume":"48","author":"Ponticelli","year":"1995","journal-title":"Kidney Int"},{"issue":"9868","key":"10.1016\/j.nephro.2021.03.001_bib0815","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0140-6736(12)61566-9","article-title":"Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial","volume":"381","author":"Howman","year":"2013","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.nephro.2021.03.001_bib0820","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1681\/ASN.2016091022","article-title":"Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy","volume":"28","author":"van den Brand","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.nephro.2021.03.001_bib0825","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.2215\/CJN.08880813","article-title":"Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy","volume":"9","author":"van den Brand","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.nephro.2021.03.001_bib0830","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/ndt\/gfh036","article-title":"Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate","volume":"19","author":"du Buf-Vereijken","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.nephro.2021.03.001_bib0835","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/ckj\/sfw152","article-title":"Intravenous cyclophosphamide and oral prednisolone is a safe and effective treatment option for idiopathic membranous nephropathy","volume":"10","author":"Mathrani","year":"2017","journal-title":"Clin Kidney J"},{"issue":"2","key":"10.1016\/j.nephro.2021.03.001_bib0840","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/nep.12569","article-title":"Tacrolimus combined with corticosteroids versus modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: randomised control trial","volume":"21","author":"Ramachandran","year":"2016","journal-title":"Nephrology (Carlton)"},{"issue":"5","key":"10.1016\/j.nephro.2021.03.001_bib0845","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2215\/CJN.07570712","article-title":"Immunosuppression for membranous nephropathy: a systematic review and meta-analysis of 36 clinical trials","volume":"8","author":"Chen","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.nephro.2021.03.001_bib0850","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.autrev.2016.12.005","article-title":"Calcineurin inhibitors versus cyclophosphamide for idiopathic membranous nephropathy: a systematic review and meta-analysis of 21 clinical trials","volume":"16","author":"Qiu","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.nephro.2021.03.001_bib0855","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1681\/ASN.V72290","article-title":"Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy","volume":"7","author":"Ambalavanan","year":"1996","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.nephro.2021.03.001_bib0860","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med"},{"issue":"9337","key":"10.1016\/j.nephro.2021.03.001_bib0865","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","article-title":"Rituximab for idiopathic membranous nephropathy","volume":"360","author":"Remuzzi","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.nephro.2021.03.001_bib0870","doi-asserted-by":"crossref","first-page":"734","DOI":"10.2215\/CJN.05231008","article-title":"Rituximab therapy for membranous nephropathy: a systematic review","volume":"4","author":"Bomback","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.nephro.2021.03.001_bib0875","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.2215\/CJN.05080610","article-title":"Rituximab therapy in idiopathic membranous nephropathy: a 2-year study","volume":"5","author":"Fervenza","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.nephro.2021.03.001_bib0880","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/sj.ki.5002628","article-title":"Rituximab treatment of idiopathic membranous nephropathy","volume":"73","author":"Fervenza","year":"2008","journal-title":"Kidney Int"},{"issue":"8","key":"10.1016\/j.nephro.2021.03.001_bib0885","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1681\/ASN.2012020181","article-title":"Rituximab in idiopathic membranous nephropathy","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.nephro.2021.03.001_bib0890","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2215\/CJN.06041108","article-title":"Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients","volume":"4","author":"Segarra","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.nephro.2021.03.001_bib0895","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.2215\/CJN.01730408","article-title":"Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy","volume":"3","author":"Ruggenenti","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2021.03.001_bib0900","article-title":"Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy","author":"Barrett","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.nephro.2021.03.001_bib0905","doi-asserted-by":"crossref","first-page":"172","DOI":"10.4049\/jimmunol.179.1.172","article-title":"Induction of passive Heymann nephritis in complement component 6-deficient PVG rats","volume":"179","author":"Spicer","year":"2007","journal-title":"J Immunol"},{"issue":"6295","key":"10.1016\/j.nephro.2021.03.001_bib0910","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725521000559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725521000559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2021.03.001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T16:17:42Z","timestamp":1741191462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725521000559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":91,"alternative-id":["S1769725521000559"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2021.03.001","relation":{},"ISSN":["1769-7255"],"issn-type":[{"value":"1769-7255","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathophysiology, diagnosis, and treatment of membranous nephropathy","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2021.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 francophone de n\u00e9phrologie, dialyse et transplantation. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}